```html

Zoonotic Cutaneous Leishmaniasis

Overview

Zoonotic cutaneous leishmaniasis (ZCL) is a skin infection caused by protozoan parasites of the genus Leishmania that are transmitted to humans through the bite of infected sand‑flies (Phlebotomine flies). The “zoonotic” label indicates that the parasite’s primary reservoir is an animal—most commonly rodents such as gerbils, jirds, or prairie dogs—rather than humans.

While ZCL can affect anyone who is exposed to an infected sand‑fly, it is most common in people living in or traveling to rural, semi‑arid regions where the sand‑fly vector thrives and where rodent reservoirs are abundant.

Global prevalence: According to the World Health Organization (WHO), cutaneous leishmaniasis accounts for roughly 1 million new cases per year. ZCL represents the majority of these cases in the Old World, especially in North Africa, the Middle East, and Central Asia (e.g., Morocco, Algeria, Tunisia, Israel, Iran, Kazakhstan). In some hyper‑endemic foci, annual incidence can exceed 500 cases per 100,000 population.<sup>[1] WHO, 2023</sup>

Symptoms

The clinical picture of ZCL is usually limited to the skin, but the appearance can vary widely.

Typical lesion progression

1. Incubation period – 2 to 12 weeks after the sand‑fly bite.
2. Papule – A small, raised, red bump (≤5 mm) appears at the bite site.
3. Plaque – The papule enlarges, becomes firm and often slightly raised.
4. Ulceration – Central necrosis develops, forming a painless ulcer with a raised, erythematous border. The base may be covered with a yellow‑white crust.
5. Healing – Over months, the ulcer slowly contracts, may leave a depressed scar or a hypopigmented area.

Complete symptom list

• Single or multiple skin lesions – Usually 1‑3 lesions, but up to 10 in heavily exposed individuals.
• Lesion size – Ranges from a few millimeters to >5 cm in diameter.
• Location – Exposed skin: face, arms, hands, legs; lesions on the head/neck are common in children.
• Absence of pain – Lesions are typically painless, though secondary bacterial infection can cause tenderness.
• Itching or burning sensation – Some patients report mild pruritus.
• Day‑time crusting & night‑time scabbing – Crusts may fall off, revealing new ulcerated tissue.
• Scarring – Atrophic or hypertrophic scars develop after healing; can be cosmetically concerning.
• Regional lymphadenopathy – Mild swelling of nearby lymph nodes in ~10 % of cases.

Causes and Risk Factors

What causes ZCL?

ZCL results from infection with one of several Leishmania species that have a zoonotic life cycle, most commonly L. major in the Old World and L. mexicana in the New World. The parasite’s life cycle includes three stages:

• Promastigote stage – Replicates in the sand‑fly’s gut after it ingests infected blood from a reservoir animal.
• Metacyclic promastigote – The infectious form transmitted during a sand‑fly bite.
• Amastigote stage – Intracellular form that multiplies inside human macrophages, leading to lesion formation.

Who is at higher risk?

• Geographic exposure – Living in or traveling to endemic rural areas.
• Occupational exposure – Farmers, shepherds, construction workers, military personnel, and eco‑tourists who spend nights outdoors.
• Age – Children often have higher reported rates due to greater outdoor activity and thinner skin.
• Poor housing – Mud‑brick homes with cracks that harbor sand‑flies.
• Lack of vector control – Absence of insecticide‑treated nets or indoor residual spraying.
• Immunocompromised state – HIV infection or immunosuppressive therapy may increase lesion number and healing time.

Diagnosis

Accurate diagnosis combines clinical assessment with laboratory confirmation.

Clinical assessment

• History of travel or residence in an endemic area.
• Typical lesion morphology and evolution.

Laboratory tests

1. Skin scraping / lesion biopsy – Examined by microscopy after Giemsa staining to detect amastigotes (the “Leishman‑Donovan bodies”). Sensitivity 60‑80 %.
2. Culture – Inoculation of specimens into Novy‑MacNeal‑Nicolle (NNN) medium; takes 1–3 weeks.
3. Polymerase chain reaction (PCR) – Highly sensitive (≈95 %) and species‑specific; increasingly the diagnostic gold standard.<sup>[2] CDC, 2022</sup>
4. Serology – Generally not useful for cutaneous disease because antibodies may be low; reserved for visceral leishmaniasis work‑up.
5. Montenegro skin test (Leishmanin skin test) – Delayed‑type hypersensitivity reaction indicating exposure, but does not differentiate active from past infection.

When to involve a specialist

If the lesion is atypical, chronic (>12 months), or if there is suspicion of mucosal involvement, referral to a dermatologist or infectious‑disease physician is advised.

Treatment Options

Treatment aims to eliminate the parasite, accelerate healing, and minimize scarring. Choice depends on lesion size, number, location, patient age, pregnancy status, and drug availability.

First‑line systemic therapies

• Miltefosine (Impavido) – Oral alkylphosphocholine; 2.5 mg/kg/day for 28 days (max 150 mg/day). Cure rates 70‑90 % for ZCL. Contraindicated in pregnancy.
• Liposomal amphotericin B (AmBisome) – IV infusion 3 mg/kg on days 1, 2, 3, 5, and 7. Used for large or multiple lesions, or in immunocompromised patients.

First‑line local therapies

• Topical paromomycin ointment – 15 % (w/w) applied 2–3 times daily for 20‑30 days. Efficacy ≈80 % for lesions ≤4 cm.<sup>[3] NIH, 2021</sup>
• Thermotherapy – Radiofrequency or microwave devices deliver controlled heat (≈50 °C) for 30‑60 seconds per lesion; cure rates 80‑95 % for lesions <5 cm.
• Intralesional sodium stibogluconate – 0.5–1 mL injected weekly for 4‑6 weeks; used when systemic toxicity is a concern.

Adjunctive measures

• Wound care – Clean the ulcer with saline, apply non‑adherent dressings, avoid scratching.
• Antibiotics – Only if secondary bacterial infection is evident (e.g., purulent discharge, erythema).
• Scar management – Silicone gel sheets or pressure therapy once the ulcer has healed to improve cosmetic outcome.

Special considerations

• Pregnancy – Preferred local treatments (thermotherapy, topical paromomycin) because systemic agents may be teratogenic.
• Children – Dosing is weight‑based; topical or thermotherapy often preferred to avoid systemic side effects.
• Immunocompromised hosts – May need prolonged systemic therapy and close follow‑up.

Living with Zoonotic Cutaneous Leishmaniasis

Even after successful treatment, the disease can impact daily life. Below are practical tips for managing skin health, psychosocial wellbeing, and preventing recurrences.

Skin care

• Keep healed lesions clean and moisturized; use fragrance‑free emollients.
• Apply sunscreen (SPF 30+) to scarred areas to prevent hyperpigmentation.
• Avoid direct trauma or excessive scratching which can reopen healed sites.

Psychological support

• Scarring, especially on the face, can cause anxiety. Consider counseling or support groups.
• Many NGOs in endemic regions provide peer‑support networks for leishmaniasis patients.

Follow‑up schedule

• First review 2 weeks after completing therapy to assess healing.
• Subsequent visits at 3 and 6 months; monitor for delayed scar hypertrophy or new lesions.
• Report any new ulcer or persistent swelling promptly.

Travel & work considerations

• If you must work or travel in endemic zones, continue using personal protective measures (see Prevention section).
• Inform employers of your condition; some workplaces may provide insect‑proof clothing or repellents.

Prevention

Prevention focuses on reducing sand‑fly exposure and controlling rodent reservoirs.

Personal protection

• Insect repellents – Apply DEET (20–30 %) or picaridin (20 %) to exposed skin; reapply every 4–6 hours.
• Protective clothing – Long‑sleeved shirts, pants, and socks; treat clothing with permethrin (0.5 % concentration) for added repellency.
• Bed nets – Sleep under insecticide‑treated nets, especially in houses without window screens.

Environmental control

• Seal cracks in walls and roofs; plaster mud‑brick houses to reduce sand‑fly resting sites.
• Remove or manage rodent habitats near dwellings (store feed in metal containers, keep yards clean).
• Community‑wide indoor residual spraying with pyrethroids once or twice yearly in high‑risk villages.

Vaccines & prophylaxis

As of 2026, no licensed human vaccine exists for ZCL, although several candidates are in clinical trials (e.g., recombinant Leishmania proteins). Research continues, and participation in vaccine trials may be an option for residents of endemic areas under strict medical supervision.

Complications

If untreated or inadequately treated, ZCL can lead to:

• Secondary bacterial infection – Cellulitis, abscess formation, or systemic infection.
• Disfiguring scars – Especially on the face; may cause social stigma.
• Mucocutaneous spread (rare) – In some L. major strains, lesions can extend to mucous membranes, causing nasal or oral ulcers.
• Chronic non‑healing ulcer – Lesions persisting >12 months may become refractory, requiring surgical excision.

When to Seek Emergency Care

---

References

1. World Health Organization. Leishmaniasis. 2023. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
2. Centers for Disease Control and Prevention. Leishmaniasis – Diagnosis. 2022. https://www.cdc.gov/leishmaniasis/diagnosis.html
Miltefosine and amphotericin B dosing guidelines: National Institutes of Health, Clinical Guidelines for Leishmaniasis, 2021.
3. National Institute of Allergy and Infectious Diseases. Cutaneous Leishmaniasis Treatment. 2021. https://www.niaid.nih.gov/diseases-conditions/cutaneous-leishmaniasis

```